ClinChoice, a global leader in clinical research, is proud to announce it has been selected to conduct a clinical study of a cutting–edge Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting solid tumors. This pivotal research represents a significant leap forward in addressing one of oncology’s most important challenges, harnessing advanced immunotherapy to specifically identify and eliminate resistant cancer cells. The study will be conducted at world-renowned cancer centers within ClinChoice’s firmly established network.
The landscape of cancer treatment has been profoundly reshaped and the adaptation of CAR-T to solid tumors is a critical next step.
Global Head of Clinical Operations and President of ClinChoice Kerry Dyson stated, “we are dedicated to patient-centric care, fostering strong site collaboration, and employing specialized skills in cohort management, precise treatment scheduling, and rigorous safety assurance to achieve optimal outcomes.”
“This new clinical study underscores our deep commitment and proven capabilities in advanced oncology trials, particularly in the complex realm of CAR-T,” stated John Balian, MD, Co-Founder, Board Member, and CEO of ClinChoice International Inc. “Our team excels at navigating the unique challenges of these studies, from meticulous patient selection and managing bridging therapies to the seasoned expertise of handling adverse events (AEs) like Cytokine Release Syndrome (CRS) and neurotoxicity, as well as ensuring essential long-term follow-up for comprehensive data,” added Chris Houchins, Global Head of Hematology/Oncology Center of Excellence for Clinical Operations.”
ClinChoice has successfully conducted 206 oncology trials over the past five years, involving more than 20,000 patients across 5,000+ clinical research sites. Our robust hematology/oncology experience includes 11 specialized CAR-T trials, underscoring our industry-wide recognition because of our mastery and flawless execution within this advanced field.
ClinChoice stands ready to continue leading innovation in cancer treatment. We are eager to collaborate globally as we invite partners from around the world to drive the commitment of groundbreaking therapies and patient-focused approaches with the goal of delivering remarkable outcomes.
About ClinChoice
ClinChoice is a leading global clinical research organization (CRO) dedicated to accelerating the development of innovative therapies for patients worldwide. With a comprehensive suite of services and deep therapeutic expertise, ClinChoice partners with pharmaceutical, biotechnology, and medical device companies to bring life-changing treatments to market.